Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease. Source
No articles found.
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutio...
Allscripts (NASDAQ: MDRX) is a leader in health...
Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global p...
Melinta Therapeutics, Inc. is dedicated to savi...
Phibro Animal Health Corporation is a leading global diversified animal health and...
Phibro Animal Health Corporation is a leading g...
AnaptysBio is a clinical-stage antibody development company advancing therapeutic ...
AnaptysBio is a clinical-stage antibody develop...
An emerging leader in the specialty pharmaceuticals industry, ANI Pharmaceuticals ...
An emerging leader in the specialty pharmaceuti...
WindowMirror's BUTTERFLY will be a collaborative SaaS (Software as a Service) plat...
WindowMirror's BUTTERFLY will be a collaborativ...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
We discover and develop medicines to defeat neurodegeneration. The science is brea...
We discover and develop medicines to defeat neu...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.